OGN Organon & Co.
OGN Organon & Co.
Healthcare · Drug Manufacturers - General
Market read
Scan convergence 1 scan as of 2026-08-17 1 bull converging
POC $13.22 · VWAP $9.75 · +40.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 watchlist
OGN Price Structure
Loading timeframes…
Peers
Every watchlist OGN belongs to, members best 30-day change first — OGN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $1.56B, diluted EPS $0.40, net income $108M (SEC filing). Across the print the stock moved +0.1% (close before → first close after).
full note →Against street estimates
How OGN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
OGN research tape
9 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.